Marazzi Fabio, Masiello Valeria, Orlandi Armando, Moschella Francesca, Chiesa Silvia, Di Leone Alba, Garufi Giovanna, Mazzarella Ciro, Sanchez Alejandro M, Casa Calogero, Bucaro Angela, De Lauretis Flavia, Borghesan Niccolo, Tagliaferri Luca, Franceschini Gianluca, Bria Emilio, Masetti Riccardo, Fabi Alessandra, Aristei Cynthia, Tortora Giampaolo, Valentini Vincenzo, Gambacorta Maria A
Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, 00168 Rome, Italy.
Fondazione Policlinico Universitario "A. Gemelli" IRCCS, UOC di Oncologia Medica, Dipartimento di Scienze Mediche e Chirurgiche, 00168 Rome, Italy.
J Pers Med. 2024 Jul 29;14(8):805. doi: 10.3390/jpm14080805.
Radiotherapy (RT) shows potential for improving local control in cases of oligoprogressive metastatic breast cancer (mBC). This retrospective analysis aims to evaluate the advantages of RT in such a clinical scenario.
We conducted a retrospective analysis including patients with mBC who received radiation therapy (RT) for up to three sites of oligoprogression while continuing systemic therapy. The study took place between January 2014 and December 2021. Our endpoints were progression-free survival after radiotherapy (PFS-AR), the rate of discontinuation of systemic therapy (RDT) at three months post-RT, and overall survival (OS). We used Cox regression analysis to perform multivariate analysis for PFS-AR.
Fifty-nine patients met the inclusion criteria. The PFS-AR was 13 months (95% CI 8.5-18.8 months). At three months, the RDT was 3% (two patients). A significant difference in median PFS-AR was observed between patients in the first + second-line group and those in the subsequent line group ( = 0.03). In the multivariate analysis conducted for PFS-AR, the biologically effective dose (BED) with α/β = 4 > 100 Gy emerged as the sole significant variable ( = 0.0017). The median overall survival (OS) was 24.4 months (95% CI 17-24.4 months).
This study is the first report on the outcomes of radiotherapy in a cohort of over 50 patients with oligoprogressive metastatic breast cancer (mBC). Our findings emphasize the significant relationship between PFS-AR, the number of ongoing lines of systemic therapy, and the BED of radiotherapy.
放射治疗（RT）在寡进展性转移性乳腺癌（mBC）病例中显示出改善局部控制的潜力。本回顾性分析旨在评估RT在这种临床情况下的优势。
我们进行了一项回顾性分析，纳入了在继续全身治疗的同时接受放射治疗（RT）至寡进展的最多三个部位的mBC患者。该研究于2014年1月至2021年12月进行。我们的终点是放疗后无进展生存期（PFS-AR）、放疗后三个月全身治疗中断率（RDT）和总生存期（OS）。我们使用Cox回归分析对PFS-AR进行多变量分析。
59名患者符合纳入标准。PFS-AR为13个月（95%CI 8.5-18.8个月）。三个月时，RDT为3%（两名患者）。一线+二线组患者与后续线组患者的中位PFS-AR存在显著差异（=0.03）。在对PFS-AR进行的多变量分析中，α/β=4且>100 Gy的生物等效剂量（BED）成为唯一的显著变量（=0.0017）。中位总生存期（OS）为24.4个月（95%CI 17-24.4个月）。
本研究是关于50多名寡进展性转移性乳腺癌（mBC）患者队列放疗结果的首份报告。我们的研究结果强调了PFS-AR、正在进行的全身治疗线数和放疗BED之间的显著关系。
